Espinoza Octavio 4

What Happened

• Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals (LGND), acquired 17 shares of LGND on June 30, 2026. The shares were purchased at $160.71 per share for a total value of approximately $2,732. This was a purchase under the company’s Employee Stock Purchase Plan (a buy, not a sale).

Key Details

• Transaction date and price: 2026-06-30 — 17 shares at $160.71/share (total ≈ $2,732).
• Shares owned after transaction: Not specified in the Form 4 filing.
• Footnote: Shares were acquired under the Ligand Employee Stock Purchase Plan and were exempt under Rule 16b-3(d) and Rule 16b-3(c) (standard exemptions for plan purchases by insiders).
• Filing timeliness: Form 4 filed on 2026-07-06. Given the June 30 transaction date, this appears to be filed after the typical 2-business-day deadline for Form 4s.

Context

• This is a small ESPP purchase (routine employee plan participation) rather than an open-market buy or option exercise. Such transactions are common and generally reflect participation in company benefit plans rather than a strong directional signal about insider sentiment.